Literature DB >> 9573110

Ambiguous role of interleukin-12 in Yersinia enterocolitica infection in susceptible and resistant mouse strains.

E Bohn1, E Schmitt, C Bielfeldt, A Noll, R Schulte, I B Autenrieth.   

Abstract

Endogenous interleukin-12 (IL-12) mediates protection against Yersinia enterocolitica in C57BL/6 mice by triggering gamma interferon (IFN-gamma) production in NK and CD4+ T cells. Administration of exogenous IL-12 confers protection against yersiniae in Yersinia-susceptible BALB/c mice but exacerbates yersiniosis in resistant C57BL/6 mice. Therefore, we wanted to dissect the different mechanisms exerted by IL-12 during Yersinia infections by using different models of Yersinia-resistant and -susceptible mice, including resistant C57BL/6 mice, susceptible BALB/c mice, intermediate-susceptible wild-type 129/Sv mice, 129/Sv IFN-gamma-receptor-deficient (IFN-gamma R-/-) mice and C57BL/6 tumor necrosis factor (TNF) receptor p55 chain-deficient (TNFR p55-/-) mice. IFN-gamma R-/- mice turned out to be highly susceptible to infection by Y. enterocolitica compared with IFN-gamma R+/+ mice. Administration of IL-12 was protective in IFN-gamma R+/+ mice but not in IFN-gamma R-/- mice, suggesting that IFN-gamma R-induced mechanisms are essential for IL-12-induced resistance against yersiniae. BALB/c mice could be rendered Yersinia resistant by administration of anti-CD4 antibodies or by administration of IL-12. In contrast, C57BL/6 mice could be rendered more resistant by administration of transforming growth factor beta (TGF-beta). Furthermore, IL-12-triggered toxic effects in C57BL/6 mice were abrogated by coadministration of TGF-beta. While administration of IL-12 alone increased TNF-alpha levels, administration of TGF-beta or TGF-beta plus IL-12 decreased both TNF-alpha and IFN-gamma levels in Yersinia-infected C57BL/6 mice. Moreover, IL-12 did not induce toxicity in Yersinia-infected TNFR p55-/- mice, suggesting that TNF-alpha accounts for IL-12-induced toxicity. Taken together, IL-12 may induce different effector mechanisms in BALB/c and C57BL/6 mice resulting either in protection or exacerbation. These results are important for understanding the critical balance of proinflammatory and regulatory cytokines in bacterial infections which is decisive for beneficial effects of cytokine therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9573110      PMCID: PMC108184          DOI: 10.1128/IAI.66.5.2213-2220.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  45 in total

1.  Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism.

Authors:  M Barral-Netto; A Barral; C E Brownell; Y A Skeiky; L R Ellingsworth; D R Twardzik; S G Reed
Journal:  Science       Date:  1992-07-24       Impact factor: 47.728

2.  Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis.

Authors:  A Barral; M Barral-Netto; E C Yong; C E Brownell; D R Twardzik; S G Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

3.  Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cells.

Authors:  I Müller; P Kropf; R J Etges; J A Louis
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

4.  In vivo neutralization of tumor necrosis factor-alpha and interferon-gamma abrogates resistance to Yersinia enterocolitica infection in mice.

Authors:  I B Autenrieth; J Heesemann
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

5.  Immune response in mice that lack the interferon-gamma receptor.

Authors:  S Huang; W Hendriks; A Althage; S Hemmi; H Bluethmann; R Kamijo; J Vilcek; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

6.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.

Authors:  D K Dalton; S Pitts-Meek; S Keshav; I S Figari; A Bradley; T A Stewart
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

7.  The cellular immune response against Yersinia enterocolitica in different inbred strains of mice: evidence for an important role of T lymphocytes.

Authors:  I B Autenrieth; M Beer; P Hantschmann; S Preger; U Vogel; B Heymer; J Heesemann
Journal:  Zentralbl Bakteriol       Date:  1993-04

8.  Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection.

Authors:  K Pfeffer; T Matsuyama; T M Kündig; A Wakeham; K Kishihara; A Shahinian; K Wiegmann; P S Ohashi; M Krönke; T W Mak
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

9.  Transforming growth factor beta (TGF-b1) plays a detrimental role in the progression of experimental Mycobacterium avium infection; in vivo and in vitro evidence.

Authors:  M Denis; E Ghadirian
Journal:  Microb Pathog       Date:  1991-11       Impact factor: 3.738

10.  Experimental Yersinia enterocolitica infection in euthymic and T-cell-deficient athymic nude C57BL/6 mice: comparison of time course, histomorphology, and immune response.

Authors:  I B Autenrieth; U Vogel; S Preger; B Heymer; J Heesemann
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

View more
  18 in total

1.  The systems biology of infection in animal models bears fruit.

Authors:  Lucas R Hoffman; Samuel I Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-12       Impact factor: 11.205

2.  Transforming growth factor beta and CD25 are important for controlling systemic dissemination following Yersinia enterocolitica infection of the gut.

Authors:  Youmin Zhong; Angelene Cantwell; Peter H Dube
Journal:  Infect Immun       Date:  2010-06-28       Impact factor: 3.441

3.  Edwardsiella piscicida Type III Secretion System Effector EseK Inhibits Mitogen-Activated Protein Kinase Phosphorylation and Promotes Bacterial Colonization in Zebrafish Larvae.

Authors:  Huifang Cao; Fajun Han; Jinchao Tan; Mingyu Hou; Yuanxing Zhang; Dahai Yang; Qin Liu
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

Review 4.  Enterobacteria and host resistance to infection.

Authors:  Eugene Kang; Alanna Crouse; Lucie Chevallier; Stéphanie M Pontier; Ashwag Alzahrani; Navoun Silué; François-Xavier Campbell-Valois; Xavier Montagutelli; Samantha Gruenheid; Danielle Malo
Journal:  Mamm Genome       Date:  2018-05-21       Impact factor: 2.957

5.  Tumor necrosis factor receptor p55-deficient mice respond to acute Yersinia enterocolitica infection with less apoptosis and more effective host resistance.

Authors:  Y X Zhao; G Lajoie; H Zhang; B Chiu; U Payne; R D Inman
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

6.  Interferon consensus sequence binding protein confers resistance against Yersinia enterocolitica.

Authors:  J Hein; V A Kempf; J Diebold; N Bücheler; S Preger; I Horak; A Sing; U Kramer; I B Autenrieth
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice.

Authors:  Sarah S Bubeck; Angelene M Cantwell; Peter H Dube
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

8.  Characterization of oral Yersinia enterocolitica infection in three different strains of inbred mice.

Authors:  Scott A Handley; Peter H Dube; Paula A Revell; Virginia L Miller
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

9.  Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease.

Authors:  S Kugathasan; L J Saubermann; L Smith; D Kou; J Itoh; D G Binion; A D Levine; R S Blumberg; C Fiocchi
Journal:  Gut       Date:  2007-08-06       Impact factor: 23.059

10.  Yersinia enterocolitica targets cells of the innate and adaptive immune system by injection of Yops in a mouse infection model.

Authors:  Martin Köberle; Annegret Klein-Günther; Monika Schütz; Michaela Fritz; Susanne Berchtold; Eva Tolosa; Ingo B Autenrieth; Erwin Bohn
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.